unwarranted starting point in such population-based studies. The most successful approach to search for allelic effects is therefore likely to require judicious choice of study populations, based on the knowledge of the trait being studied-in some cases a relatively unadmixed population, in other cases a diverse, more admixed population. In designing pharmacogenomic studies, it is therefore imperative for the clinical researcher to be aware and appreciate the richness and diversity of alleles that exist (but to very differing degrees) in each racial and ethnic group, rather than to study such groups with the idea that they are genetically 'pure. ' Adverse drug reactions, due in large part to interindividual variability in drug response, ranks between the fourth and sixth leading cause of death in the US. 1 Pharmacogenetics and pharmacogenomics represent 'the studies of variability in drug response due to heredity.' Pharmacogenetic advances, which have exploded during the past decade due to our rapidly increasing knowledge of the human genome, should help in the substantial reduction of drug-caused morbidity and mortality. In a recent listing of many dozens of pharmacogenetic differences, 2 the majority of the diversity occurs in drug metabolism genes, with some present in drug receptor and transporter genes, and many others not yet explained on a molecular basis. In principle, a pharmacogenetic disorder might reflect allelic differences in any 'susceptibility gene. ' If one considers that a drug (or other environmental chemical, metabolite, or heavy metal) may theoretically act as an agonist or antagonist (or activator or inhibitor) of virtually any gene product (target) in the cell, then it is likely that most-if not every-gene in the human genome might be considered either directly or indirectly to be a susceptibility gene.
3 Pharmacogenetic differences are often 10-fold to more than 40-fold between the highest and lowest individual in any given population, 2 yet the mean difference between any two ethnic populations is rarely greater than 2-or 3-fold. 4 The fact-that interindividual variance is much greater than group variation-is a hallmark of complex traits and is the subject of this invited 'Perspectives' article.
RACE AND ETHNICITY
The term 'race' is derived from Latingeneratio (n) and generare (v)-meaning 'generation' and 'to engender', respectively. Webster's Dictionary defines race as 'any of the different varieties of mankind, mainly the Caucasoid, Mongoloid, and Negroid groups, distinguished by color of skin and type of hair.' Also, 'any geographical, national, or tribal ethnic grouping.' Some anthropologists regard Arabs, Jews, Latinos and Spaniards as 'distinct races', whereas most would prefer to call these 'ethnic groups.' Most regard the origin of human races similar to that of animal or plant spec-iation, ie extreme geographic and genetic isolation for thousands of years in the absence of outbreeding. In brief, therefore, 'racial characteristics' is an ancient term, basically referring to 'how a human being looks', or 'is perceived', by another. A better understanding as to how these races originated, especially how the development of each race has been influenced by environment and the evolution of genes, and the unexpectedly high genetic admixture discovered between races in many geographic areas, should increase the success with which human disease can be ameliorated by pharmaceuticals.
OUT OF AFRICA-TWICE?
Virtually all anthropologists now agree that the evolution of Homo sapiens began in Africa. [5] [6] [7] [8] [9] The human lineage is estimated to have diverged from other primates about 5 million years ago, with the chimpanzee being our closest living relative. The most primitive human ancestors yet discovered belong to the genus Australopithecus (which includes 'Lucy') that lived more than 3 million years ago in the Rift Valley. Early members of our own genus, Homo erectus, and its near relative, Homo ergaster, arose about 2.5 million years ago in the Rift Valley. These 'archaic' hominids are thought to have migrated out of Africa approximately 1.7 million years ago to begin nucleus populations in Europe, the Middle East, and Asia.
Fossils of Homo sapiens, dating between 200 000 and 80 000 years ago, have been found throughout the 'Old World'-Africa, Europe, and Asia. These Homo sapiens shared with us important anatomical features (skull size and shape) and behavioral attributes (use of blades, bone tools, pigments and dyes, burial goods, art, trade, hunting, and distinct environmental resources). These humans subsequently scattered to New Guinea and Australia, Micronesia and Polynesia, and the Americas.
The means by which modern humans (Homo sapiens sapiens) emerged is a matter of debate between proponents of two opposing theories.
Supporters of the Multiregional Theory
The Pharmacogenomics Journal contend that modern human populations developed independently from archaic hominid populations (Homo erectus or Homo ergaster) in Africa, Europe, and Asia; early modern groups evolved in parallel with each other, and there was 'gene flow' between these groups to give rise to present populations. On the other hand, supporters of the Displacement Theory, commonly known as 'Out of Africa,' propose that contemporary human populations are derived from a single modern population group that left Africa between 200 000 and 80 000 years ago. This founding group migrated throughout the Old World, displacing any surviving archaic hominids ( Figure 1 ). Recent studies on mitochondrial DNA, for example, have shown convincingly that Neanderthal man (Homo neandertalensis) existed in Europe as recently as 29 000 years ago but interbred very little, if any, with Homo sapiens. 10 Hence, although almost all scientists agree that our early hominid relatives arose in Africa, most disagree on when the direct ancestors of present-day humans left Africa to populate the entire planet. Figure 2 depicts the theoretical divergence for a hypothetical gene of 32 alleles amongst the three principal races. The diagram shows ten African-, seven Asian-and four Caucasian-specific alleles, and six alleles shared between Africans and Asians, three alleles shared between Africans and Caucasians, one allele shared between Asians and Caucasians, and one allele shared among all three races. Because of advances in travel-mostly by water-in the last two millennia (100 generations), and by land and air much more recently, the mixing of these racespecific alleles has rapidly increased. This means that, for any given gene, the number of new haplotypes today must be much larger than that of 2000 years ago. For example, using bloodgroup antigens, population geneticists have shown that some populations of Central and South America are 'trihybrid,' in that they have been derived from Caucasian, African and Amerindian-and only during the past 400 years (ෂ20 generations).
OUR PERCEPTION OF 'RACE'
The thousands of generations of Homo sapiens sapiens (Figure 2) are amply sufficient for allelic differences in genes to have evolved-genes that encode such characteristics as skin color, type of hair, or body size and shape. For example, the African pygmy is small with dark skin, highly coordinated and agile, elongated eyes and large nostrils, traits that in all likelihood were selected for optimal success while hunting-and-gathering in a very humid tropical climate (the surface area of a small body is greater in relation to its volume, enabling more efficient heat exchange). The Eskimo has more subcutaneous fat, skin lighter than that of the pygmy, narrow eyes and small nostrils, again to improve his likelihood of survival in a very cold dry climate (heat is conwww.nature.com/tpj served through extra body fat; narrow eyes and small nostrils minimize heat loss while breathing). Lower levels of skin pigment may have evolved and been selected for in Northern European populations eating a vitamin Dpoor cereal-based diet in locations where the sun exposure is low. 5 How many genes might determine skin color, hair color and texture, facial traits, and body size and shape? From genomics research, it now appears highly likely that surprisingly few genes might determine most characteristics that contribute to one's perceived racial stereotype. 11 Between 28 000 and 40 000 genes are estimated to comprise the entire human genome, yet as few as dozens-several hundred at mostare likely to be found responsible for most racial features. Clearly, dark skin has evolved and been selected for in tropical populations, likely as protection against tropical sun. The case for differences in skin color has now been linked to the melanocortin-stimulating hormone receptor-1 (MC1R) gene. This gene has multiple alleles, and certain alleles are seen in most people with red hair and skin that burns rather than tans; these same alleles are rarely seen in Caucasians who tan rather than burn, and are never seen in Africans, suggesting that variant alleles in the MC1R gene are probably an adaptation to differences in sun-exposure levels in these distinct populations. 12 It is anticipated that variations in hair color and texture, facial structure, and body size and shape between human races might also be controlled by allelic differences in a small number of genes that affect these superficial, visible differences. The same is predicted to be true for alleles of genes that do not affect superficial racial or ethnic features (eg blood pressure, ability to taste, capacity to metabolize drugs). The true variations between human races are expected, therefore, to be only minor sequence deviations in receptor, transporter, metabolism, developmental signal transduction, transcription factor, or some equivalent, genes. This emerging concept is consistent with the hundreds of ethnic studies of drug-metabolizing enzymes 4 that generally show no more than 2-to 3-fold differences between races or ethnic groupswhereas differences between individuals, within any one race or ethnic group, are often 10-to greater than 40-fold. Granted, race-specific alleles can be major factors in determining a pharmacogenetic phenotype. For example, the CYP1A1*4 allele is not seen in Africans, the CYP2C19*3 allele (poor metabolizer, PM) is common in and specific to Asians, and the NAT2*14 series of alleles (slow acetylator) appears to be African-specific. 13, 14 Race-specific and allelic variants are of course also going to be widespread in the Human Genome Project. For example, even though the common consensus ('wild-type,' reference) sequence has been agreed upon as the CYP2D6*1 (extensive metabolizer, EM) and the NAT2*1 (rapid acetylator) alleles, 13, 14 the Human Genome Database contains the rare CYP2D6*5 allele (in which the entire CYP2D6 gene is deleted, PM) and the very rare NAT2* 12A allele (rapid acetylator).
Recent knowledge in DNA resequencing and human genetics has revealed the races that comprise Homo sapiens sapiens are far more amalgamated than had previously been imagined. An average population from any urban area in the world is expected to include about 85% of all human variant alleles. Differences among populations from the same continent contribute another 6% of the variability, and from different continents 9-13% of genetic variation. 15 This means the popular perception that 'human races are genetically distinct' is largely false; this would be especially true in countries that are 'melting pots' for numerous ethnic groups-such as the United States.
Since 1993, the US National Institutes of Health Revitalization Act has mandated clinical trials to enroll minority group members, based on traditionally defined racial and ethnic characteristics, and the documentation of results by race. 16 There are scientific reasons to include racial and ethnic groups in certain kinds of clinical studies; however, as we understand the large number of common alleles in individuals from different ethnic groups (Figure 2) , there are compelling reasons to study highly discordant individuals based on the quantitation of their trait (eg EMs vs PMs for a given drug) rather than on their ethnicity.
The Case for Using Ethnic Populations
What valid reasons are there, for choosing to perform certain types of genetic studies in populations with relatively low allelic variation? Principal among these is that certain disorders are disproportionately more common in certain ethnic groups. Examples include cystic fibrosis in Northern Europeans, sickle-cell disease in certain African sub-groups, and Tay The Case for Using Populations Classified by 'Phenotype' Rather than Ethnic Origin As stated above, variation of a trait between individuals within a race is usually much greater in magnitude than the mean variation between races. This is particularly true of multifactorial traits, which may be influenced (to differing degrees) by dozens, or several hundred genes at most, as well as by environmental factors. In such instances, the restriction of the study population to a particular race or ethnic group would clearly limit the effectiveness of the study. In the future, it is anticipated that specific human pharmacogenetic phenotypeseg CYP2D6 PMs vs EMs, slow vs rapid N-acetylators, or glucose-6-phosphate dehydrogenase deficiency vs normal levels of activity-might represent more
The Pharmacogenomics Journal well-defined and genetically distinct populations than particular 'racial' or 'ethnic' populations. The biggest difficulty with using admixed populations is the possibility of disregarding epistatic effects (ie the 'sensitive' allele in one genetic background need not be the 'sensitive' allele in another background), and overcoming this drawback presents researchers with a major challenge.
The most important goal for the researcher in clinical studies of ethnic groups, therefore, is to recognize and understand each of the racial and ethnic groups that are chosen for study, in order to correctly interpret the data. Some groups (eg African-American, Caribbean, Panamanian) might be expected to exhibit a large degree of allelic diversity, whereas other groups (eg sub-Saharan African, Inuit, Finn) would be expected to show much less richness of diverse alleles. Nature Genetics now requires that authors explain why they make use of a particular ethnic population and how classification was achieved, and are asking reviewers to consider those parameters when judging the merits of a manuscript; 16 this new journal editorial policy underscores our conclusions in this invited 'Perspectives' article.
Ultimately, we will need to know the pertinent (medically relevant) genotype for all populations or individuals under medical care, in order to make the best decisions in care and prevention. This should be accomplished by mechanisms based on scientific reason, rather than mandates for 'racial inclusion' in all human studies.
